Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
hRPGRstb is an investigational **gene therapy transgene construct** consisting of a stabilized, truncated version of the human **retinitis pigmentosa GTPase regulator** gene designed for treatment of **X-linked retinitis pigmentosa** caused by **RPGR** mutations. It has been developed by **AGTC** for delivery in recombinant AAV ocular gene therapy vectors, including vectors using the proprietary **AAV2tYF** capsid and a **GRK1** photoreceptor-directed promoter. The stabilization strategy removes repetitive regions that can cause sequence instability during vector engineering and manufacturing, while preserving therapeutic RPGR function. Its intended mechanism is **gene replacement**, restoring RPGR expression in retinal photoreceptors to slow or prevent degeneration of rods and cones and preserve vision.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on hRPGRstb.